Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

In England, about 600 people will benefit from the daily pill that helps treat lung cancer as it becomes routinely available on the NHS.